Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M118Revenue (TTM) $M124Net Margin (%)18.8Altman Z-Score-1.5
Enterprise Value $M94.7EPS (TTM) $0.2Operating Margin %44.8Piotroski F-Score7
P/E(ttm)4.7Beneish M-Score-2.9Pre-tax Margin (%)18.8Higher ROA y-yY
Price/Book6.010-y EBITDA Growth Rate %--Quick Ratio6.0Cash flow > EarningsY
Price/Sales0.95-y EBITDA Growth Rate %--Current Ratio6.3Lower Leverage y-yN
Price/Free Cash Flow2.9y-y EBITDA Growth Rate %--ROA % (ttm)8.3Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M106ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with VVUS

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

VVUS is held by these investors:



VVUS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Varghese Santosh TChief Medical Officer 2017-04-04Sell440$1.08-3.7view
NORTH TIDE CAPITAL, LLC10% Owner 2017-03-10Sell1,149,400$1.16-10.34view
NORTH TIDE CAPITAL, LLC10% Owner 2017-03-07Sell192,800$1.08-3.7view
NORTH TIDE CAPITAL, LLC10% Owner 2017-03-02Sell160,100$1.13-7.96view
NORTH TIDE CAPITAL, LLC10% Owner 2017-02-27Sell333,000$1.14-8.77view
NORTH TIDE CAPITAL, LLC10% Owner 2017-02-22Sell161,800$1.11-6.31view
NORTH TIDE CAPITAL, LLC10% Owner 2017-02-16Sell305,090$1.1-5.45view
NORTH TIDE CAPITAL, LLC10% Owner 2017-02-13Sell176,410$1.11-6.31view
NORTH TIDE CAPITAL, LLC10% Owner 2017-02-08Sell563,527$1.06-1.89view
NORTH TIDE CAPITAL, LLC10% Owner 2017-02-03Sell78,633$1.12-7.14view

Press Releases about VVUS :

Quarterly/Annual Reports about VVUS:

News about VVUS:

Articles On GuruFocus.com
VIVUS to Extend Return Date of STENDRA Commercial Rights Jun 30 2016 
VIVUS Announces Date of 2016 First Quarter Business Update and Financial Results Teleconference Apr 19 2016 
Biotech Momentum Indicators: Achaogen (AKAO), Novartis (NVS), VIVUS (VVUS) Apr 01 2015 
5-year lows: PICO Holdings Inc, Black Box Corp, Vivus, and Electro Rent Corp. Mar 29 2015 
A Look at Pharma Company Dermira's Performance Mar 27 2015 
5-year lows: Vivus, Synta Pharmaceuticals Inc, MVC Capital Inc, and Kemet Corp. Feb 08 2015 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Weekly Three-Year Low Highlight: VVUS, RALY, WILN, COVS Mar 25 2014 
Billionaires Hold Four Stocks, 59% Off Sep 30 2013 
Unique Investor Kyle Bass Unloads Five May 29 2013 

More From Other Websites
VIVUS Announces Date of 2017 First Quarter Business Update and Financial Results Teleconference Apr 25 2017
VIVUS (VVUS) Down 14.1% Since Earnings Report: Can It Rebound? Apr 10 2017
Orexigen Releases Q4 Results, Vivus Reacquires Stendra from Sanofi Mar 30 2017
VIVUS to Regain Commercial Rights for Stendra from Sanofi Mar 28 2017
Vivus Inc. stock rises 4.6% after regaining certain commercial rights for Stendra from Sanofi Mar 27 2017
VIVUS, Inc. Reacquires STENDRA(R) (Avanafil) Commercial Rights from Sanofi Mar 27 2017
7 Most Popular Diet Pills That Work Fast Without Exercise Mar 15 2017
VIVUS, Inc. :VVUS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 15, 2017 Mar 15 2017
Markets Rally Late to Close in the Green: Today's Research Reports on Immunomedics and VIVUS Mar 10 2017
VIVUS (VVUS) Beats on Q4 Earnings, Revenues Increase Y/Y Mar 09 2017
Edited Transcript of VVUS earnings conference call or presentation 8-Mar-17 9:30pm GMT Mar 08 2017
Vivus posts 4Q profit Mar 08 2017
VIVUS Reports Fourth Quarter and Full Year 2016 Financial Results Mar 08 2017
VIVUS Announces Date of 2016 Fourth Quarter Business Update and Financial Results Teleconference Feb 28 2017
Biotech's Rally Shows No Signs of Slowing Down: Today's Reports on Eyegate Pharmaceuticals and VIVUS Feb 22 2017
Top 5 Biotech Stocks for 2017 Jan 30 2017
VIVUS Licenses Rights to PAH Drugs from Selten Pharma Jan 11 2017
VIVUS and Selten Pharma Announce Agreement for the Development and Commercialization Rights to... Jan 09 2017
Arena Pharmaceuticals Dumps Belviq Weight Loss Drug Jan 06 2017
VIVUS (VVUS): Will Qsymia & Stendra Sales Improve in 2017? Jan 03 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)